Figure 7.
Figure 7. CTRP-1 prevents platelet thrombosis in the nonhuman primate Folts vascular injury model and re-establishes and maintains blood flow. Panels A and B show typical individual flow traces recorded. Treatment with CTRP-1 (0.5 mg/kg) prevents platelet thrombosis and re-establishes blood flow through the injured carotid artery (A). No treatment effect was seen in a BSA-treated control (B). Arrows indicate the time of treatment. (L) The result of the complete study (n = 3, each group; shown is the mean ± SEM). Pretreatment stenotic blood flow was similar in all 3 groups. BSA-treated control animals showed permanent occlusion with no residual blood flow (▪); treatment with 0.5 mg/kg (□) and 1.0 mg/kg CTRP-1 (▦) reestablished blood flow, which was maintained throughout the study. Average blood flow is shown over 2 time intervals: a 30-minute period immediately following cessation of intervention and a subsequent 2-hour time window indicating longer-term effects.

CTRP-1 prevents platelet thrombosis in the nonhuman primate Folts vascular injury model and re-establishes and maintains blood flow. Panels A and B show typical individual flow traces recorded. Treatment with CTRP-1 (0.5 mg/kg) prevents platelet thrombosis and re-establishes blood flow through the injured carotid artery (A). No treatment effect was seen in a BSA-treated control (B). Arrows indicate the time of treatment. (L) The result of the complete study (n = 3, each group; shown is the mean ± SEM). Pretreatment stenotic blood flow was similar in all 3 groups. BSA-treated control animals showed permanent occlusion with no residual blood flow (▪); treatment with 0.5 mg/kg (□) and 1.0 mg/kg CTRP-1 (▦) reestablished blood flow, which was maintained throughout the study. Average blood flow is shown over 2 time intervals: a 30-minute period immediately following cessation of intervention and a subsequent 2-hour time window indicating longer-term effects.

Close Modal

or Create an Account

Close Modal
Close Modal